MAC
RXRX icon

Mason & Associates (California)’s Recursion Pharmaceuticals RXRX Stock Holding History

Mason & Associates (California)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,300
Closed -$94.6K – 172
2026
Q1 		$94.6K Buy
33,300
+135
+0.4% +$522 0.02% 159
2025
Q4 		$136K Hold
33,165
– – 0.03% 156
2025
Q3 		$162K Hold
33,165
– – 0.03% 132
2025
Q2 		$168K Hold
33,165
– – 0.04% 120
2025
Q1 		$175K Buy
+33,165
New +$242K 0.04% 113

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mason & Associates (California)'s RXRX Position: Q2 2026 in Review

Mason & Associates (California) sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 33,300 shares — an estimated $94.6K sold.

Mason & Associates (California) first reported a position in RXRX in Q1 2025 and held it in 5 quarters. The position peaked at $175K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Mason & Associates (California) reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Mason & Associates (California) sold 33,300 Recursion Pharmaceuticals shares in Q2 2026, an estimated $94.6K.
  • Mason & Associates (California) first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Mason & Associates (California)'s Recursion Pharmaceuticals position peaked at $175K in Q1 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mason & Associates (California)'s 13F filing for Q2 2026, filed 23 Jul 2026.